throughout the cancer development stages. If the same DNA methylation changes could be monitored in cfDNA released by tumor one could trace the emergence of the cancer, monitor the progression, and predict effects of treatments. Despite these advantages, current cfDNA detection is significantly hampered by the lack of sensitivity because only a very small amount of cfDNA could be obtained from plasma and serum. cfDNA is also heavily fragmented (between 200~400 bp), adding additional challenges.
Faced with these challenges, Wen et al. [7] invent methylated CpG tandems amplification and sequencing (MCTASeq), a method that takes advantage of the fact that CpG tandems are highly enriched in the CpG island-containing promoters of human genome. These CpGs are typically unmethylated but tend to gain hypermethylation in hepatocellular carcinoma (HCC) [6] . The cfDNAs released into circulation carry the same hypermethylation patterns, thereby providing accurate information of the presence of HCC in patients. In their new method, cfDNA is treated with bisulfite, during which non-methylated C (cytosine) is converted to U (uracil) while methylated C remains unaffected. They then use a pair of primers to specifically amplify DNA loci that contain hypermethylated CGCGCGG, a sequence frequently presented in CpG islands and tend to be methylated in cancer tissues. The focus on the CGC-GCGG-containing loci may miss other potential markers; however, it offers the sensitivity required for methylation detection in cfDNA. Validation data of MCTA-Seq shows that it is highly reproducible and sensitive, with the detection limit down to as low as 7.5 pg (~2.5 haploid genome equivalents). Existing biomarkers that are frequently hypermethylated in human cancers [8] , such as VIM, SEPT9, NDRG2 and RASSF1 [8] , could be detected with high sensitivity by using MCTA-Seq. The method, although limited by the requirement of the CGCGCGG sequence content, is genome-wide and offers sufficient information about CpG island methylation changes in HCC.
Wen et al. applied the new method to detect tumor-specific CGI methylation with plasma samples from HCC patients, cirrhosis patients, and normal individuals. Two types of biomarkers have been identified for early stage HCC diagnosis (Figure 1 
